Liquid formulation of decitabine and use of the same

Details Liquid formulation of decitabine and use of the same Liquid formulation of decitabine and use of the same

2006-01-03

2006-01-03

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S042000, C514S043000

Reexamination Certificate

active

06982253

ABSTRACT:
Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.

REFERENCES:
patent: 3817980 (1974-06-01), Vorbruggen et al.
patent: 4022889 (1977-05-01), Bannister et al.
patent: 4477442 (1984-10-01), Skulnick et al.
patent: 4910021 (1990-03-01), Davis et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5700640 (1997-12-01), Voss et al.
patent: 6225325 (2001-05-01), Jacob
patent: 6255293 (2001-07-01), Kimchi
patent: 6309666 (2001-10-01), Hatano et al.
patent: 6613753 (2003-09-01), Rubinfeld et al.
patent: WO 02/069903 (2002-09-01), None
Sheikhnejad, G. et al., “Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine”,J. Mol. Biol., 1999, pp. 2021-2034, vol. 285.
Goffin, J. et al., “DNA methyltransferase inhibitors—state of the art”,Annals of Oncology, 2002, pp. 1699-1716, vol. 13.
Wijermans, P. et al., “Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients”,Journal of Clinical Oncology, Mar. 2000, pp. 956-962, vol. 18, No. 5.

Affiliated with

Also associated with

Rating

Liquid formulation of decitabine and use of the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Liquid formulation of decitabine and use of the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liquid formulation of decitabine and use of the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3572441